Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health
Pneuma Respiratory, a leading med-tech and pharmaceutical company, is pioneering innovative solutions in inhaled respiratory therapeutics aimed at transforming respiratory care. With a focus on treating smoking-related lung conditions, Pneuma is introducing a groundbreaking aerosol generation technology that enhances the delivery of medications directly to the lungs, offering a more efficient and effective treatment approach. This advancement has the potential to significantly improve the standard of care for millions of patients globally.
Pneuma Respiratory is accelerating its mission to improve respiratory health by forging strategic partnerships to rapidly deliver new solutions on a large scale, particularly in the reduced-risk nicotine field. The company is also focusing on the development of treatments for chronic obstructive pulmonary disease (COPD), non-small cell lung cancer, and precancerous conditions. With 54 issued patents and over 100 pending applications, Pneuma is positioning itself as a leader in the field, driving innovation in respiratory treatments. Its breakthrough technology is providing significant harm reduction opportunities in inhaled nicotine, with promising applications for a range of respiratory diseases.
Disrupting the Market with Advanced Technology
Pneuma’s next-generation technology is designed to disrupt the market with its innovative approach to both reduced-risk nicotine delivery and pharmaceutical applications. For nicotine-related products, Pneuma’s technology provides several key advantages:
- Non-Heated Technology: Unlike traditional nicotine delivery methods, Pneuma’s technology avoids thermal degradation byproducts such as formaldehyde, acetaldehyde, and benzene. This results in a cleaner, less harmful delivery of nicotine.
- Water-Based Solutions: Pneuma offers a more natural alternative to traditional inhalation methods, eliminating unnecessary chemical additives, making it a healthier option for users.
- Reduced Secondhand Nicotine Exposure: Designed with non-smokers in mind, Pneuma’s products minimize the impact of nicotine exposure on non-users, addressing one of the major concerns with traditional smoking and vaping.
In the pharmaceutical space, Pneuma’s technology offers highly effective benefits:
- Ultra-Fine Droplet Precision: The company’s technology allows for precise control over sub-micron aerosol droplet sizes. This enables targeted delivery of medications to specific regions of the lungs, improving treatment effectiveness.
- High Respirable Fractions: Pneuma’s devices ensure that over 90% of the aerosol reaches the lungs, significantly reducing the systemic dose needed to achieve the desired therapeutic effect.
- Fully Digital Breath-Actuated Delivery: Pneuma’s devices automatically deliver medication as patients breathe, ensuring ease of use, improving adherence, and enhancing patient comfort.
Expanding Market Reach Through Strategic Partnerships
Pneuma is strategically prioritizing the reduced-risk nicotine market as part of its go-to-market strategy. The company recognizes the potential for significant global health impact through the adoption of its innovative nicotine-delivery technology. By accelerating the use of its life-saving technologies, Pneuma is aiming to help shift the world toward a smokeless future and potentially save millions of lives. The company is actively partnering with global leaders in the reduced-risk nicotine product space, as well as major healthcare and pharmaceutical companies specializing in therapeutic areas.
“We are committed to bringing better treatment options to people who need them the most,” said Eric Hunter, CEO and Co-Founder of Pneuma Respiratory. “Over the past year, we’ve expanded our patent portfolio, fine-tuned our device and app designs, and strengthened our industry partnerships. We are focused on making a lasting impact on respiratory health.”
Impacting Global Health
Pneuma is on the brink of releasing pivotal third-party study results that demonstrate the effectiveness of its non-heated reduced-risk nicotine product. These studies show that Pneuma’s product significantly reduces harmful compounds and secondhand nicotine exposure, addressing major public health concerns. In addition to its work in nicotine-related products, Pneuma’s inhaled therapeutics show broad potential for treating other serious lung diseases, including COPD and non-small cell lung cancer.
The company’s fully digital technology further enhances treatment effectiveness by reducing side effects commonly associated with traditional medications. Pneuma’s innovative approach is poised to play a critical role in improving respiratory health outcomes globally, particularly for individuals affected by smoking-related lung conditions.
